TY - JOUR
T1 - Effect of Extended-Release Niacin on Carotid Intima Media Thickness, Reactive Hyperemia, and Endothelial Progenitor Cell Mobilization
T2 - Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial
AU - Guerra, Andres
AU - Rangan, Bavana Venkata
AU - Coleman, Ameka
AU - Xu, Hao
AU - Kotsia, Anna
AU - Christopoulos, Georgios
AU - Sosa, Alan
AU - Chao, Howard
AU - Han, Henry
AU - Abdurrahim, Guthbudeen
AU - Roesle, Michele
AU - de Lemos, James A
AU - McGuire, Darren K
AU - Packer, Milton
AU - Banerjee, Subhash
AU - Brilakis, Emmanouil S
PY - 2015/12
Y1 - 2015/12
N2 - BACKGROUND: Thirty-eight patients with intermediate (30%-60% diameter stenosis) saphenous vein graft lesions were randomized to extended-release niacin (ER-niacin) or placebo for 12 months. We sought to evaluate the impact of ER-niacin on carotid intima media thickness (CIMT), endothelial function, and endothelial progenitor cell (EPC) mobilization. METHODS: Carotid B-mode ultrasound was used to image the common and internal carotid arteries, at baseline and at 12 months after enrollment. Reactive hyperemia peripheral arterial tonometry, as assessed with EndoPAT 2000 (Itamar Medical, Inc) and EPC mobilization assessed with flow cytometry, were measured at enrollment, and at 1 and 12 months. RESULTS: The baseline clinical characteristics were similar in the two study groups. High-density lipoprotein cholesterol levels tended to increase more in the ER-niacin group (5.9 ± 8.7 mg/dL vs 1.4 ± 7.1 mg/dL; P≤.14). Between baseline and 12 months, right common carotid artery (0.96 ± 0.44 mm vs 0.70 ± 0.24 mm; P≤.04), and left common carotid artery (0.80 ± 0.30 mm vs 0.70 ± 0.20 mm; P≤.08) CIMT tended to decrease in the ER-niacin group, compared with no change in the placebo group. The change in logarithmic reactive hyperemia index between 1 month and 12 months was similar in patients receiving ER-niacin vs placebo (0.003 ± 0.12 vs -0.058 ± 0.12; P≤.39), whereas EPC mobilization increased in the ER-niacin group and decreased in the placebo group (8.65 ± 28.41 vs -5.87 ± 30.23 EPC colony forming units/mL of peripheral blood; P≤.02). CONCLUSIONS: ER-niacin did not have a significant impact on CIMT or endothelial function, but increased EPC mobilization.
AB - BACKGROUND: Thirty-eight patients with intermediate (30%-60% diameter stenosis) saphenous vein graft lesions were randomized to extended-release niacin (ER-niacin) or placebo for 12 months. We sought to evaluate the impact of ER-niacin on carotid intima media thickness (CIMT), endothelial function, and endothelial progenitor cell (EPC) mobilization. METHODS: Carotid B-mode ultrasound was used to image the common and internal carotid arteries, at baseline and at 12 months after enrollment. Reactive hyperemia peripheral arterial tonometry, as assessed with EndoPAT 2000 (Itamar Medical, Inc) and EPC mobilization assessed with flow cytometry, were measured at enrollment, and at 1 and 12 months. RESULTS: The baseline clinical characteristics were similar in the two study groups. High-density lipoprotein cholesterol levels tended to increase more in the ER-niacin group (5.9 ± 8.7 mg/dL vs 1.4 ± 7.1 mg/dL; P≤.14). Between baseline and 12 months, right common carotid artery (0.96 ± 0.44 mm vs 0.70 ± 0.24 mm; P≤.04), and left common carotid artery (0.80 ± 0.30 mm vs 0.70 ± 0.20 mm; P≤.08) CIMT tended to decrease in the ER-niacin group, compared with no change in the placebo group. The change in logarithmic reactive hyperemia index between 1 month and 12 months was similar in patients receiving ER-niacin vs placebo (0.003 ± 0.12 vs -0.058 ± 0.12; P≤.39), whereas EPC mobilization increased in the ER-niacin group and decreased in the placebo group (8.65 ± 28.41 vs -5.87 ± 30.23 EPC colony forming units/mL of peripheral blood; P≤.02). CONCLUSIONS: ER-niacin did not have a significant impact on CIMT or endothelial function, but increased EPC mobilization.
KW - atherosclerosis
KW - cardiac surgery
KW - carotid artery disease
KW - niacin
KW - saphenous vein graft
UR - http://www.scopus.com/inward/record.url?scp=84948745278&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84948745278&partnerID=8YFLogxK
M3 - Article
C2 - 26630643
AN - SCOPUS:84948745278
SN - 1042-3931
VL - 27
SP - 555
EP - 560
JO - Journal of Invasive Cardiology
JF - Journal of Invasive Cardiology
IS - 12
ER -